Focal laser ablation provides a minimally invasive treatment that targets and ablates (destroys) only specific parts of glands, organs, or other tissue needing treatment, while preserving the surrounding and remaining tissue. This generally produces faster recovery, fewer side effects, and less pain and discomfort for patients that may not be good candidates or are inoperable for traditional open surgery*.
CLS AB is an innovative medical device company within healthcare technology and therapy. With people in mind, we are at the forefront of developing more precise, more effective interventional healthcare solutions.
Our TRANBERG™ systems marketed in the US by CLS Americas provide minimally invasive alternatives to traditional treatments and are FDA 510(k) cleared.
Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally, saving healthy tissue.
Patient Focused
Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed the TRANBERG™ Thermal Therapy System for image-guided focal laser ablation.
Through research by our co-founder, professor Karl-Göran Tranberg, CLS has gained significant knowledge and experience with treating/killing cancer tumors using laser ablation under image guidance.
Today, our TRANBERG™ Thermal Therapy System is optimized for minimally invasive focal therapy of soft tissue and used to treat patients with localized prostate cancer.
Learn about our progress within the Mobile Service Provider Model enabling more clinics to treat prostate cancer patients.
Listen to a podcast episode with Michael Magnani, President of CLS Americas and Dr Garrett D. Pohlman, urologist at Kearney and the host of the Prostate Health Podcast. They had an engaging discussion around the key features and benefits of using the TRANBERG system for the treatment of low to intermediate localized prostate cancer.
We are happy to introduce Joel Hix, Director of Clinical Operations at CLS Americas. Joel has over 15 years of senior management experience in operations, sales, marketing, and service with leading medical device manufacturers including Boston Scientific and Healthtronics.
*All the focal therapies report low rates of complications, and high rates of continence and erectile function preservation. Klotz et al. Curr Opin Urol. (2020).
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
Clinical Laserthermia Systems Americas Inc.
6080 Center Drive, 6th Floor
Los Angeles, CA 90045 USA
Phone: +1 (949) 504-5440
E-mail: contact-us@clinicallaser.com
©Copyright 2023 CLS AB. All rights reserved.
MM-2022-026/Rev1
